Yoon Jimi, Oh Chee Won, Kim Chi Yeon
Department of Dermatology, Institute of Health Science, School of Medicine, Gyeongsang National University, Jinju, Korea.
Ann Dermatol. 2011 Dec;23(Suppl 3):S343-5. doi: 10.5021/ad.2011.23.S3.S343. Epub 2011 Dec 27.
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib.
凡德他尼是一种每日口服一次的抗癌药物，它通过靶向血管内皮生长因子受体、表皮生长因子受体酪氨酸激酶以及在转染依赖性肿瘤细胞增殖和存活过程中发生重排的关键信号通路，选择性地抑制癌症中的关键信号通路。与凡德他尼相关的最常报告的不良事件包括腹泻、转氨酶升高、无症状的校正QT间期延长和高血压。尽管已经报告了一些随机双盲研究，包括凡德他尼引起的皮肤不良事件以及这些一般症状，但尚未报告史蒂文斯-约翰逊综合征（SJS）病例。本文展示了一例由凡德他尼诱发的SJS病例。
